Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4850882
Max Phase: Preclinical
Molecular Formula: C26H26F3N7
Molecular Weight: 493.54
Molecule Type: Unknown
Associated Items:
ID: ALA4850882
Max Phase: Preclinical
Molecular Formula: C26H26F3N7
Molecular Weight: 493.54
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CN1CCN(CC#Cc2n[nH]c3ccc4nc(-c5c[nH]nc5C(F)(F)F)c5c(c4c23)CCCC5)CC1
Standard InChI: InChI=1S/C26H26F3N7/c1-35-11-13-36(14-12-35)10-4-7-20-23-21(33-32-20)9-8-19-22(23)16-5-2-3-6-17(16)24(31-19)18-15-30-34-25(18)26(27,28)29/h8-9,15H,2-3,5-6,10-14H2,1H3,(H,30,34)(H,32,33)
Standard InChI Key: UMAQLJIXCUTUBC-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 493.54 | Molecular Weight (Monoisotopic): 493.2202 | AlogP: 4.00 | #Rotatable Bonds: 2 |
Polar Surface Area: 76.73 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.50 | CX Basic pKa: 7.65 | CX LogP: 5.16 | CX LogD: 4.71 |
Aromatic Rings: 4 | Heavy Atoms: 36 | QED Weighted: 0.41 | Np Likeness Score: -1.13 |
1. Dayal N, Řezníčková E, Hernandez DE, Peřina M, Torregrosa-Allen S, Elzey BD, Škerlová J, Ajani H, Djukic S, Vojáčková V, Lepšík M, Řezáčová P, Kryštof V, Jorda R, Sintim HO.. (2021) 3H-Pyrazolo[4,3-f]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo., 64 (15.0): [PMID:34288692] [10.1021/acs.jmedchem.1c00330] |
Source(1):